MOUNTAIN VIEW, Calif., Feb. 2 /PRNewswire/ -- Aviron (Nasdaq: AVIR) today
announced that it has priced its offering of common stock at $50.00 per share
and has increased the size of the offering from 3,000,000 shares to
4,000,000 shares. Aviron also increased the size of its offering of
5 1/4 percent convertible subordinated notes due 2008 from $150 million
aggregate principal amount to $200 million. The notes have a conversion price
of $62.50.
The underwriters have the option to purchase up to an additional
600,000 shares (200,000 from selling stockholders and 400,000 from the
company) and an additional $30 million principal amount of notes to cover
over-allotments, if any. The managing underwriters for the offering are
Morgan Stanley Dean Witter, JP Morgan and SG Cowen Securities Corporation.
Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.
Copies of the prospectuses relating to the public offerings may be
obtained by contacting Morgan Stanley Dean Witter, 1585 Broadway, New York,
NY, 10036, 212-761-4000; JP Morgan, 1 Bush Street, San Francisco, CA, 94104,
415-439-3000; or SG Cowen Securities Corporation, 1 Financial Square,
New York, NY, 10005, 212-495-7305.
SOURCE Aviron
 back to top
Related links:
http://www.aviron.com
Company News On-Call:
http://www.prnewswire.com/comp/114000.html or fax,
800-758-5804, ext. 114000
CONTACT:
John Bluth, 650-919-3716, or Asha Jennings,
650-919-1429, or investors, Fred Kurland, 650-919-6666, all of
Aviron; or Camela Stuby of Fleishman-Hillard, 212-453-2000, for
Aviron
|
